Fly News Breaks for December 23, 2019
Dec 23, 2019 | 11:46 EDT
Piper Jaffray analyst Danielle Brill thinks Sarepta's (SRPT) deal with Roche (RHHBY) for ex-U.S. rights to their microdystrophin gene therapy, SRP-9001, is "highly validating" for the program. The analyst believes the large deal signifies safety remains clean in the ongoing Study-102, manufacturing is on-track, and latest efficacy data look good. Brill reiterates an Overweight rating on Sarepta's shares, with a $210 price target.
News For SRPT;RHHBY From the Last 2 Days
There are no results for your query SRPT;RHHBY